You are here

Jesse Boehm


Sharifnia, Tanaz et al. Emerging Opportunities for Target Discovery in Rare Cancers. Cell Chem. Biol. 2017. Sept (24): 1075-1091.

Johannessen, C et al. Progress towards precision functional genomics. Curr Opin Syst Biol. 2017. Apr (2): 74-83.

Berger AH, et al. High-throughput phenotyping of lung cancer somatic mutations. Cancer Cell. 2016 Aug 8;30(2):214-28.

Hong AL, et al. Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun. 2016 Jun 22;7:11987.

Kim E, et al. Systematic functional interrogation of rare cancer variants identifies oncogenic allelesCancer Discov. 2016 Jul;6(7):714-26.

Boehm JS, Golub TR. An ecosystem of cancer cell line factories to support a cancer dependency map. Nat Rev Genet. 2015 Jul;16(7):373-4.

Jesse Boehm, Ph.D.

Jesse Boehm is the associate director of the Broad Institute’s Cancer Program and an institute scientist at the Broad. In addition, he directs the Cancer Cell Line Factory (CCLF) initiative, and is a principal investigator for the Broad’s Cancer Model Development Center (part of the National Cancer Institute’s Human Cancer Models Initiative). Boehm is also the recipient of a Broad Institute Merkin Fellowship.

In these roles, he works closely with Cancer Program director Todd Golub in the scientific planning and strategic execution of program projects, collaborations, and activities, with particular focus on senior strategic leadership of the Broad’s Dependency Map initiative, together with co-principal investigators Golub and institute member William Hahn.

In addition, Boehm leads a research laboratory focused on developing methods and tools to accelerate the translation of cancer genomics into cancer therapeutics. Active projects include developing pipelines for personalized testing of tumor vulnerabilities as part of the CCLF and assessing the tumorigenic potential of thousands of new cancer mutations as part of the Cancer Program’s Target Accelerator initiative. The research group has an ultimate goal of making “precision functional genomics” a reality.

Previously, Boehm worked as a research scientist in the Broad Cancer Program to generate and deploy functional genomics tools for cancer.

Boehm received his B.S. in biology from MIT and his Ph.D. from Harvard University, Division of Medical Sciences. For his graduate studies, he worked in the Hahn laboratory at DFCI, where he developed and utilized new experimental models of cellular transformation, the process by which cells become cancerous.

June 2017